Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-05-10-Speech-4-315-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20120510.69.4-315-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"Following the presentation of the European Court of Auditors’ annual report for the financial year 2010, the European Parliament’s Committee on Budgetary Control carried out the financial audit of the European Union general budget in respect of the European Medicines Agency as part of the 2010 discharge procedure. The Committee’s primary responsibility is to ensure and verify that the Community budget is implemented in a regular and efficient manner. The discharge report notes that the main issue with the European Medicines Agency is that its management board has yet to approve the action plan drafted during last year’s discharge procedure to remedy existing issues. The report points out that a number of cases of conflicts of interest within the agency were revealed recently, and the Committee does not recommend granting discharge until these are clarified. At its meeting in late March, the Committee decided to postpone the granting of discharge, as it found that in order for the authority to be granted discharge, some additional issues concerning its 2010 management needed to be clarified. I supported the postponement of granting discharge at both the Committee vote and the vote in plenary."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples